Tracking cancer treatment effects on pregnant women and their babies
Official title: Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being
Run by Cooper Norcross Health · NCT02749474 · Data updated 2026-11-12
This study is tracking pregnant women with cancer to see how their treatments affect both their health and the health of their babies.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 400 (estimated) |
| Sponsor | Cooper Norcross Health Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Camden, New Jersey) |
| Status | Recruiting |
| Started | July 1, 2003 |
| Main results expected | July 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT02749474 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant women diagnosed with cancer within six weeks before their last menstrual period or within six months after the end of their pregnancy.
✕Probably not a fit
Patients diagnosed with cancer more than six months after the end of a pregnancy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to follow pregnant women diagnosed with cancer to assess the impact of their treatment options on both their health and the health of their children. It collects data on diagnosis methods, treatment choices, and maternal and neonatal outcomes at delivery, with follow-ups extending into childhood and adulthood. The study recognizes that cancer complicates approximately 1 in 1000 pregnancies, with breast cancer being the most common type diagnosed during this period. The research seeks to provide insights into the safety and outcomes of cancer treatments during pregnancy.
Why it matters
Potential benefit: If successful, this study could improve understanding of how cancer treatments during pregnancy affect both mothers and their children, leading to better clinical guidelines.
How similar studies have gone: Previous studies have shown that treatment during pregnancy can be safe and effective, but this specific registry approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any pregnant woman diagnosed with cancer within 6 weeks before her last menstrual period or 6 months after her end of pregnancy either by delivery or miscarriage. Exclusion Criteria: * Women diagnosed with cancer more than 6 months after the end of a pregnancy.
Where it's running
-
Cooper University Hospital
Camden, New Jersey, United States Recruiting
Study contacts
- Principal investigator: Elyce H Cardonick, MD — Cooper Health System
- Study coordinator: Elyce H Cardonick, MD
- Email: cancerandpregnancy@cooperhealth.edu
- Phone: 856342 2065
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.